Nuzenio

Advanced Breast Cancer

Advanced Breast Cancer news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 11 latest news signals 9 publisher sources 100/100 entity strength

Latest news

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer - biopharmaapac.combiopharmaapac.com · Mon, 10 Aug 2026 04:37:45 GMT Inetetamab-Pyrotinib Regimen Shows High pCR in HER2-Positive Breast Cancer - Targeted OncologyTargeted Oncology · Sat, 08 Aug 2026 15:11:40 GMT Trastuzumab Rezetecan Improves Progression-Free Survival in HER2-Positive Metastatic Breast Cancer - The ASCO PostThe ASCO Post · Fri, 07 Aug 2026 14:42:22 GMT FDA Flashback: Breast Cancer Decisions and News From July 2026 - OncLiveOncLive · Thu, 06 Aug 2026 22:03:53 GMT HER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer - The ASCO PostThe ASCO Post · Thu, 06 Aug 2026 13:47:28 GMT Scientists identify promising new target behind treatment resistance in advanced breast cancer - Medical XpressMedical Xpress · Tue, 04 Aug 2026 12:00:05 GMT Leptomeningeal Disease in HER2-Positive Metastatic Breast Cancer - MedPage TodayMedPage Today · Mon, 03 Aug 2026 16:47:14 GMT Dr Tolaney on Questions Regarding Treatment Duration in HER2+ Metastatic Breast Cancer - OncLiveOncLive · Thu, 30 Jul 2026 15:06:05 GMT

Timeline

Mon, 10 Aug 2026 04:37:45 GMTAkeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer - biopharmaapac.com

Sat, 08 Aug 2026 15:11:40 GMTInetetamab-Pyrotinib Regimen Shows High pCR in HER2-Positive Breast Cancer - Targeted Oncology

Fri, 07 Aug 2026 14:42:22 GMTTrastuzumab Rezetecan Improves Progression-Free Survival in HER2-Positive Metastatic Breast Cancer - The ASCO Post

Thu, 06 Aug 2026 22:03:53 GMTFDA Flashback: Breast Cancer Decisions and News From July 2026 - OncLive

Thu, 06 Aug 2026 13:47:28 GMTHER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer - The ASCO Post

Tue, 04 Aug 2026 12:00:05 GMTScientists identify promising new target behind treatment resistance in advanced breast cancer - Medical Xpress

Related explainers

HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.

Connected entities

Metastatic Breast Cancer6 live mentions Positive Metastatic Breast4 live mentions Cancer3 live mentions Akeso Doses First2 live mentions Patient2 live mentions Phase II Trial2 live mentions Ivonescimab Combination2 live mentions Pyrotinib Regimen Shows2 live mentions High2 live mentions Positive Breast Cancer2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Advanced Breast Cancer.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

9 distinct publisher/source names are currently connected to this entity page.